DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Wu H, Shi J, Luo Y. et al.
Evaluation of ruxolitinib for steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation.
JAMA Netw Open 2021;
4 (01) e2034750
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.